David Friedman

In a report published Monday, Morgan Stanley analyst David Friedman reiterated an Underweight rating on Theravance (NASDAQ: THRX), but lowered the price target from $12.00 to $7.00. In the report, Morgan Stanley noted, “In light of the THRX/TBPH split, we are updating our model for Royalty Co. (we...

In a report published Tuesday, Morgan Stanley analyst David Friedman reiterated an Equal-Weight rating on Idenix Pharmaceuticals (NASDAQ: IDIX), and raised the price target from $5.00 to $24.50. In the report, Morgan Stanley noted, “We are increasing our price target to $24.50 in light of Merck's...

In a report published Thursday, Morgan Stanley analyst David Friedman reiterated an Underweight rating on Incyte (NASDAQ: INCY), but removed the $14.00 price target. In the report, Morgan Stanley noted, “OS and PFS data trended together and seem to be generating a clinically meaningful pt benefit...

In a report published Thursday, Morgan Stanley analyst David Friedman reiterated an Underweight rating on Theravance (NASDAQ: THRX), but removed the $12.00 price target. In the report, Morgan Stanley noted, “Anoro (Umec/VI) recently launched in the US. In light of the slow Breo launch, Street...

On Tuesday, Morgan Stanley initiated coverage on shares of GW Pharmaceuticals (NASDAQ: GWPH) with an Overweight rating and $103 price target, sending the shares $15 higher to $61. Analyst David Friedman believes the company's cannabis platform “has strong potential, with the epilepsy program...

In a report published Tuesday, Morgan Stanley analyst David Friedman reiterated an Overweight rating on Synageva BioPharma (NASDAQ: GEVA), but removed the $118.00 price target. In the report, Morgan Stanley “Synageva recently started an MPS3b pt study (n=6) where they will be assessing the degree...

In a report published Wednesday, Morgan Stanley analyst David Friedman reiterated an Overweight rating on Chimerix (NASDAQ: CMRX), but removed the $34.00 price target. In the report, Morgan Stanley noted, “Chimerix announced today that based on urgent patient need, they have negotiated with the...

In a report published Thursday, Morgan Stanley analyst David Friedman downgraded the rating on Auxilium Pharmaceuticals (NASDAQ: AUXL) from Equal-Weight to Underweight, but reiterated the $15.00 price target. In the report, Morgan Stanley noted, “We are DG AUXL to UW from EW as we do not believe...

In a report published Tuesday, Morgan Stanley analyst David Friedman initiated coverage on Ultragenyx Pharmaceutical (NASDAQ: RARE) with an Overweight rating and $81.00 price target. In the report, Morgan Stanley noted, “Ultragenyx is an orphan disease focused co. that has in-licensed a series of...

In a report published Friday, Morgan Stanley analyst David Friedman reiterated an Underweight rating and $13.00 price target on Theravance (NASDAQ: THRX). In the report, Morgan Stanley noted, “THRX is still planning for a split by 1Q14. While we await details on the ultimate capital structure and...

In a report published Tuesday, Morgan Stanley analyst David Friedman downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Equal-weight and raised its price target to $72.00 from $54.00. According to the report, the move was based on a more balanced risk/reward post recent stock...

In a report published Wednesday, Morgan Stanley analyst David Friedman downgraded Neurocrine Biosciences (NASDAQ: NBIX) to EqualWeight from OverWeight, raising its price target to $16.00. According to the report, the price target increase is based on a set of model changes including adding VMAT...

In a report published Tuesday, Morgan Stanley analyst David Friedman initiated coverage on Relypsa (NASDAQ: RLYP) with an Overweight rating and $57.00 price target. In the report, Morgan Stanley noted, “We are OW Relypsa as we believe patiromer has $850+mn revenue potential in hyperK+. Patiromer...